Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEURODEGENERATIVE DISEASE

Multimodal imaging in RBD — present and future

Nature Reviews Neurology volume 14, pages 574–576 (2018)Cite this article

Subjects

Multimodal imaging in neurodegenerative disorders can provide insights on structural, functional and neurochemical alterations that might not be possible via clinical testing alone. New findings on multimodal imaging in idiopathic REM sleep behaviour disorder (iRBD) have implications for the relationship between iRBD, the clinical phenotype of Parkinson disease and the underlying substrate of Lewy body disease, particularly for understanding the pathophysiology and designing disease-modifying therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Boeve, B. F. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann. NY Acad. Sci. 1184, 17–56 (2010).

    Article  Google Scholar 

  2. St Louis, E. K. & Boeve, B. F. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin. Proc. 92, 1723–1736 (2017).

    Article  Google Scholar 

  3. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 24, 197–211 (2003).

    Article  Google Scholar 

  4. Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618–628 (2018).

    Article  Google Scholar 

  5. Boeve, B. F. Idiopathic REM sleep behaviour disorder in the development of Parkinson’s disease. Lancet Neurol. 12, 469–482 (2013).

    Article  Google Scholar 

  6. Miyamoto, T. et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67, 2236–2238 (2006).

    Article  CAS  Google Scholar 

  7. Iranzo, A. et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9, 1070–1077 (2010).

    Article  CAS  Google Scholar 

  8. Ehrminger, M. et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139, 1180–1188 (2016).

    Article  Google Scholar 

  9. Albin, R. L. et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55, 1410–1412 (2000).

    Article  CAS  Google Scholar 

  10. Postuma, R. B., Gagnon, J. F., Bertrand, J. A., Genier Marchand, D. & Montplaisir, J. Y. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84, 1104–1113 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA

    Bradley F. Boeve

  2. Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN, USA

    Kejal Kantarci

Authors
  1. Bradley F. Boeve
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kejal Kantarci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradley F. Boeve.

Ethics declarations

Competing interests

B.F.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH (UO1 NS 100620, R34 AG056639, U01 AG045390, U54 NS092089, R01 AG041797, P50 AG016574, U01 AG006786 and R44 AG 050326), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. K.K. serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc. She receives research support from Avid Radiopharmaceuticals, Eli Lilly. She is funded by the National Institutes of Health (NIH grants: U01 NS 100620, RF1 AG 57547, P50 AG 16574, U01 AG 045390, R01 NS 80816, RF1 AG 51504, U01 AG 52943, RF1 AG5 5151, R01 AG 55121 and U01 AG 52943) and the Alzheimer’s Drug Discovery Foundation (ADDF).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boeve, B.F., Kantarci, K. Multimodal imaging in RBD — present and future. Nat Rev Neurol 14, 574–576 (2018). https://doi.org/10.1038/s41582-018-0054-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-018-0054-3

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research